-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Ventus Therapeutics announced the completion of a $140 million Series C financing
Ventus' R&D pipeline targets the inflammasome and DNA sensing pathways of the innate immune system
Ventus' ReSOLVE platform combines structural biology and protein science expertise with its proprietary computational chemistry capabilities to discover and characterize previously unknown or poorly understood protein surface binding pockets Bound small molecule structures
▲Ventus product pipeline (Ventus official website)
Its lead project VENT-01 is a peripherally restricted small molecule inhibitor targeting NLRP3
Ventus' third project targets cyclic GMP-AMP synthase (cGAS), a key regulator of the stimulator of interferon genes (STING) pathway
References:
References:[1] Ventus Therapeutics Closes $140 Million Series C Financing.